Literature DB >> 24337198

[Therapeutic management in early disease stages of systemic sclerosis : early diagnosis - early symptoms - early problems].

M Frerix1, F M P Meier, W Hermann, U Müller-Ladner.   

Abstract

Increasing knowledge about the rare disease systemic sclerosis and improved diagnostic methods in the course of recent decades has led to the possibility of diagnosing systemic sclerosis at earlier disease stages. However, earlier diagnosis has an impact on routine clinical care of affected patients, and rheumatologists need to know about early symptoms, their diagnosis, and clinical management. In this review, the therapeutic management of early disease stages is described. In particular, we focus on diagnostic tools which should be included in a "basic assessment" of systemic sclerosis and discuss the diagnosis and treatment options of early symptoms such as Raynaud phenomenon, puffy fingers and hand edema, digital ulcers, calcinosis cutis, and cardiopulmonary, renal, and gastrointestinal involvement. Finally, the options of early immunosuppressive treatment and autologous stem cell transplantation for patients with rapid progressive and severe disease are reviewed.

Entities:  

Mesh:

Year:  2013        PMID: 24337198     DOI: 10.1007/s00393-013-1270-2

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  106 in total

Review 1.  [Management of digital ulcers in patients with systemic sclerosis].

Authors:  G Riemekasten; U Hoffmann; C Sunderkötter; N Weiss; A Kuhn
Journal:  Dtsch Med Wochenschr       Date:  2011-12-16       Impact factor: 0.628

2.  Microcirculatory and clinical effects of serial percutaneous application of carbon dioxide in primary and secondary Raynaud's phenomenon.

Authors:  J Schmidt; P Monnet; B Normand; R Fabry
Journal:  Vasa       Date:  2005-05       Impact factor: 1.961

Review 3.  Recent advances for the management of Raynaud phenomenon using botulinum neurotoxin A.

Authors:  Sandeep Mannava; Johannes F Plate; Austin V Stone; Thomas L Smith; Beth P Smith; L Andrew Koman; Christopher J Tuohy
Journal:  J Hand Surg Am       Date:  2011-09-08       Impact factor: 2.230

4.  Endocardial and myocardial involvement in systemic sclerosis--is there a relevant inflammatory component?

Authors:  Robert Dinser; Marc Frerix; Florian M P Meier; Karin Klingel; Andreas Rolf
Journal:  Joint Bone Spine       Date:  2012-12-10       Impact factor: 4.929

5.  Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factors.

Authors:  C Sunderkötter; I Herrgott; C Brückner; P Moinzadeh; C Pfeiffer; J Gerss; N Hunzelmann; M Böhm; T Krieg; U Müller-Ladner; E Genth; E Schulze-Lohoff; M Meurer; I Melchers; G Riemekasten
Journal:  Br J Dermatol       Date:  2009-01-13       Impact factor: 9.302

6.  An International, Web-Based, Prospective Cohort Study to Determine Whether the Use of ACE Inhibitors prior to the Onset of Scleroderma Renal Crisis Is Associated with Worse Outcomes-Methodology and Preliminary Results.

Authors:  Marie Hudson; Murray Baron; Ernest Lo; Joanna Weinfeld; Daniel E Furst; Dinesh Khanna
Journal:  Int J Rheumatol       Date:  2010-09-14

7.  Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study.

Authors:  Jonathan Goldin; Robert Elashoff; Hyun J Kim; Xaiohong Yan; David Lynch; Diane Strollo; Michael D Roth; Philip Clements; Daniel E Furst; Dinesh Khanna; Srainnapha Vasunilashorn; Gang Li; Donald P Tashkin
Journal:  Chest       Date:  2009-11       Impact factor: 9.410

8.  Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study.

Authors:  Alice Bérezné; Brigitte Ranque; Dominique Valeyre; Michel Brauner; Yannick Allanore; David Launay; Véronique Le Guern; Jean-Emmanuel Kahn; Louis-Jean Couderc; Joël Constans; Pascal Cohen; Alfred Mahr; Christian Pagnoux; Eric Hachulla; André Kahan; Jean Cabane; Loïc Guillevin; Luc Mouthon
Journal:  J Rheumatol       Date:  2008-05-01       Impact factor: 4.666

Review 9.  Micro- and macrovascular treatment targets in scleroderma heart disease.

Authors:  Theodoros Dimitroulas; George Giannakoulas; Haralambos Karvounis; Alexandros Garyfallos; Lucas Settas; George D Kitas
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

10.  A score of risk factors associated with ischemic digital ulcers in patients affected by systemic sclerosis treated with iloprost.

Authors:  Paola Caramaschi; Nicola Martinelli; Alessandro Volpe; Sara Pieropan; Ilaria Tinazzi; Giuseppe Patuzzo; Helal Mahamid; Lisa Maria Bambara; Domenico Biasi
Journal:  Clin Rheumatol       Date:  2009-03-20       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.